期刊
RHEUMATOLOGY
卷 50, 期 9, 页码 1542-1550出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/ker192
关键词
Rheumatoid arthritis; Treatment; Small molecule; Signalling; kinases; fostamatinib; tofacitinib
类别
Orally available small molecule compounds have recently been developed for the treatment of RA, and inhibitors of signalling cascades, specifically inhibitors of kinases, have reached advanced stages of clinical development. The p38 mitogen-activated protein kinase blockers have shown poor clinical response despite encouraging preclinical data. In contrast, inhibitors of the non-receptor tyrosine kinases, spleen tyrosine kinase and janus kinase 3, have demonstrated a significant clinical efficacy together with an acceptable safety profile. We herein present a review on published preclinical and clinical data on these new drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据